SCHEMBL5814108

SCHEMBL5814108

COc1ccc(Nc2cc3c(cc2Nc2ccc(OC)cc2)C(=O)NC3=O)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.88
SRC P12931 4/20 0.88
MAPT P10636 4/20 0.63
PRKD3 O94806 3/20 0.63
PRKCG P05129 3/20 0.63
PRKCB P05771 3/20 0.63
PRKCA P17252 3/20 0.63
PRKCH P24723 3/20 0.63
PRKCI P41743 3/20 0.63
PRKCE Q02156 3/20 0.63
PRKCQ Q04759 3/20 0.63
PRKCZ Q05513 3/20 0.63
PRKCD Q05655 3/20 0.63
PRKD1 Q15139 3/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
TDP1 Q9NUW8 3/20 0.63
ABL1 P00519 1/20 0.63
ABL2 P42684 1/20 0.63
MAPK1 P28482 3/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8833729 0.94 EGFR (1.00) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL8834581 0.85 EGFR (0.66) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL8835073 0.83 EGFR (0.72) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL8834532 0.81 EGFR (0.76) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL8834183 0.81 EGFR (1.00) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL8833563 0.81 EGFR (0.61) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL5821140 0.80 EGFR (0.64) EGFRSRCMAPTMEN1KMT2A
SCHEMBL8834837 0.80 KMT2A (0.64) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL8833940 0.80 STK10 (0.61) EGFRSRCMAPTPRKD3PRKCG
SCHEMBL8834258 0.78 EGFR (0.73) EGFRSRCMAPTPRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142591-A1 DAPH analogs and inhibition of protein aggregation WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2006-06-29 US claimed
WO-2006047514-A2 DAPH ANALOGS AND INHIBITION OF PROTEIN AGGREGATION WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2006-05-04 WO claimed
US-20060142591-A1 DAPH analogs and inhibition of protein aggregation WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH 2006-06-29 US disclosed
WO-2006047514-A2 DAPH ANALOGS AND INHIBITION OF PROTEIN AGGREGATION WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2006-05-04 WO disclosed
US-5663336-A IMIDATION OF DIAMINOPHTHALIC ACID TO FORM KINASE INHIBITORS AS ANTITUMOR AGENTS CIBA-GEIGY CORPORATION (US) 1997-09-02 US disclosed
US-5491144-A KINASE INHIBITORS, ANTITUMOR AGENTS CIBA-GEIGY CORPORATION (US) 1996-02-13 US disclosed
EP-0516588-B1 Substituted diaminophtalimides and analogues CIBA GEIGY AG (CH) 1994-07-13 EP disclosed
EP-0516588-A1 Substituted diaminophtalimides and analogues CIBA-GEIGY AG (CH) 1992-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142591-A1 DAPH analogs and inhibition of protein aggregation DAP3, DAPK1, DAPK3 EGFR 3637/4885SRC 965/4885MAPT 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.